Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 19, 2023 - Issue 3
Submit an article Journal homepage
1,427
Views
2
CrossRef citations to date
0
Altmetric
Zoster

The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy

Angioletta Lasagnaa Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyCorrespondence[email protected]
View further author information
,
Dalila Meleb Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Federica Bergamib Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Domiziana Alaimoa Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Chiara Daucciaa Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Nicolò Alessioa Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Giuditta Comollib Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Francesca Pasia Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Alba Muzzic Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Viola Novellic Medical Direction, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Fausto Baldantid Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy;b Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
,
Paolo Pedrazzolie Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy;a Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
&
Irene Cassanitid Department of Clinical Surgical Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy;b Molecular Virology Unit, Department of Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, Pavia, ItalyView further author information
 show all
Article: 2288282 | Received 19 Aug 2023, Accepted 22 Nov 2023, Published online: 01 Dec 2023

References

  • Kawai K, Yawn B. Risk of herpes zoster in cancer patients and the promise of new vaccines. J Infect Dis. 2019;220(1):1–6. doi:10.1093/infdis/jiy626.
  • Tayyar R, Ho D. Herpes simplex virus and varicella zoster virus infections in cancer patients. Viruses. 2023;15(2):439. doi:10.3390/v15020439.
  • Qian J, Heywood AE, Karki S, Banks E, Macartney K, Chantrill L, Liu B. Risk of herpes zoster prior to and following cancer diagnosis and treatment: a population-based prospective cohort study. J Infect Dis. 2019;220(1):3–11. doi:10.1093/infdis/jiy625.
  • Serra F, Cassaniti I, Lilleri D, Pedrazzoli P, Baldanti F, Lasagna A. Herpes zoster in patients with solid tumors treated with immune checkpoint inhibitors. Immunotherapy. 2022;14(6):389–93. doi:10.2217/imt-2021-0333.
  • Lasagna A, Cassaniti I, Sacchi P, Baldanti F, Bruno R, Pedrazzoli P. Infectious complications and immunotherapy: old pitfalls and new horizons. Future Oncol. 2022;18(22):2377–81. doi:10.2217/fon-2022-0277.
  • Kano Y, Tohyama M, Aihara M, Matsukura S, Watanabe H, Sueki H, Iijima M, Morita E, Niihara H, Asada H, et al. Sequelae in 145 patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms: survey conducted by the Asian Research Committee on Severe Cutaneous Adverse Reactions (ASCAR). J Dermatol. 2015;42(3):276–82. doi:10.1111/1346-8138.12770.
  • SHINGRIX: product information. [accessed 2023 July 28]. https://www.fda.gov/vaccines-blood-biologics/vaccines/shingrix.
  • Pedrazzoli P, Lasagna A, Cassaniti I, Ferrari A, Bergami F, Silvestris N, Sapuppo E, Di Maio M, Cinieri S, Baldanti F. Vaccination for herpes zoster in patients with solid tumors: a position paper on the behalf of the Associazione Italiana di Oncologia Medica (AIOM). ESMO Open. 2022;7(4):100548. doi:10.1016/j.esmoop.2022.100548.
  • Working Group on Vaccination against Herpes Zoster. Public health commission of the interterritorial council of the national health system. Recomendaciones de vacunación frente a herpes zóster [Vaccination recommendations against shingles]. Madrid: Ministry of Health; 2021 Mar 25 [accessed 2023 July 28]. Spanish. https://www.mscbs.gob.es/fr/profesionales/saludPublica/prevPromocion/vacunaciones/programasDeVacunacion/docs/HerpesZoster_RecomendacionesVacunacion.pdf.
  • Vink P, Delgado Mingorance I, Maximiano Alonso C, Rubio-Viqueira B, Jung KH, Rodriguez Moreno JF, Grande E, Marrupe Gonzalez D, Lowndes S, Puente J, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: a randomized trial. Cancer. 2019;125(8):1301–12. doi:10.1002/cncr.31909.
  • Lasagna A, Agustoni F, Percivalle E, Borgetto S, Paulet A, Comolli G, Sarasini A, Bergami F, Sammartino JC, Ferrari A, et al. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. ESMO Open. 2021;6(5):100272. doi:10.1016/j.esmoop.2021.100272.
  • Cassaniti I, Ferrari A, Comolli G, Sarasini A, Gregorini M, Rampino T, Lilleri D, Baldanti F. Characterization of varicella-zoster (VZV) specific T cell response in healthy subjects and transplanted patients by using enzyme linked immunospot (ELISpot) assays. Vaccines (Basel). 2021;9(8):875. doi:10.3390/vaccines9080875.
  • Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13(Suppl 1):S31–S4. doi:10.4103/sja.SJA_543_18.
  • Taoka M, Ochi N, Yamane H, Yamamoto T, Kawahara T, Uji E, Kosaka Y, Takeda K, Nagasaki Y, Nakanishi H, et al. Herpes zoster in lung cancer patients treated with PD-1/PD-L1 inhibitors. Transl Cancer Res. 2022;11(3):456–62. doi:10.21037/tcr-21-2764.
  • Jones D, Como CN, Jing L, Blackmon A, Neff CP, Krueger O, Bubak AN, Palmer BE, Koelle DM, Nagel MA, et al. Varicella zoster virus productively infects human peripheral blood mononuclear cells to modulate expression of immunoinhibitory proteins and blocking PD-L1 enhances virus-specific CD8+ T cell effector function. PLoS Pathog. 2019;15(3):e1007650. doi:10.1371/journal.ppat.1007650.
  • Laing KJ, Ouwendijk WJD, Koelle DM, Verjans GM. Immunobiology of varicella-zoster virus infection. J Infect Dis. 2018;218(suppl_2):S68–74. doi:10.1093/infdis/jiy403.
  • Lasagna A, Pedrazzoli P, Bruno R, Sacchi P. Postvaccination immune-mediated hepatitis: what do we really know? Immunotherapy. 2023;15(9):627–30. doi:10.2217/imt-2023-0038.
  • Lasagna A, Lenti MV, Cassaniti I, Sacchi P. Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report. Immunotherapy. 2022;14(12):915–25. doi:10.2217/imt-2021-0342.
  • Lasagna A, Brunello A, Silvestris N, Pedrazzoli P, Di Maio M, Cinieri S. Italian oncologists and vaccinations against infectious diseases: results of a survey of the Italian Association of Medical Oncology. Tumori. 2023 Aug;10:3008916231191547. doi:10.1177/03008916231191547.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.